电邮这篇文章 Vaccine safety for COVID-19 prevention
- 作者: Romanov B.K.1, Alpatov S.P.1, Bogush N.V.1, Borozdenko D.A.1, Buyanova N.M.1, Ganshina I.V.1, Dibirova G.O.1, Dmitrieva N.B.1, Kalinina E.V.1, Kirillova A.V.1, Kiseleva N.M.1, Kukushkin G.V.1, Leonteva T.I.1, Maximov M.L.1, Markina E.V.1, Mileshina S.E.1, Tsitsuashvili M.D.1, Yurov D.E.1
-
隶属关系:
- N.I. Pirogov Russian National Research Medical University
- 期: 卷 27, 编号 3 (2021)
- 页面: 273-280
- 栏目: Clinical pharmacology and pharmaceuticals
- URL: https://bakhtiniada.ru/0869-2106/article/view/101159
- DOI: https://doi.org/10.17816/0869-2106-2021-27-3-273-280
- ID: 101159
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
BACKGROUND: In 2021, the Uppsala Monitoring Center of the World Health Organization included 52 vaccines for coronavirus disease-2019 (COVID-19) prevention in the international database, VigiBase, and almost immediately, this group of medicines (drugs) took the lead in the increased rate of reported adverse reactions (ARs).
AIM: This study aimed to review the case reports of ARs from COVID-19 vaccines in the VigiBase database.
MATERIALS AND METHODS: Statistical analysis of cases that describe ARs in the international pharmacovigilance VigiBase database was performed.
RESULTS: On May 12, 2021, the VigiBase database included 26,099,906 reports that describe AR cases on drugs, including 585,744 reports of AR on vaccines for COVID-19 prevention. Serious ARs after immunization with these vaccines were registered in 31.5% of reports, including 0.9% fatal and 1.3% life-threatening. Headache (37.1% of reports), pyrexia (31.1%), chills (23.2%), and fatigue (22.7%) were most frequently recorded.
CONCLUSIONS: More data are required to confirm the association between the COVID-19 vaccines and the increased risk of ARs following their use.
关键词
作者简介
Boris Romanov
N.I. Pirogov Russian National Research Medical University
编辑信件的主要联系方式.
Email: bkr@ya.ru
ORCID iD: 0000-0001-5429-9528
MD, Dr. Sci. (Med.)
俄罗斯联邦, MoscowSergey Alpatov
N.I. Pirogov Russian National Research Medical University
Email: immunosport@rambler.ru
ORCID iD: 0000-0003-2233-7301
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowNadezhda Bogush
N.I. Pirogov Russian National Research Medical University
Email: nadinbogush@gmail.com
俄罗斯联邦, Moscow
Denis Borozdenko
N.I. Pirogov Russian National Research Medical University
Email: borozdenko@phystech.edu
ORCID iD: 0000-0002-6797-9722
俄罗斯联邦, Moscow
Natalia Buyanova
N.I. Pirogov Russian National Research Medical University
Email: natasha-buyanova@mail.ru
ORCID iD: 0000-0002-4073-475X
俄罗斯联邦, Moscow
Irina Ganshina
N.I. Pirogov Russian National Research Medical University
Email: july1119661@rambler.ru
ORCID iD: 0000-0003-4049-7907
俄罗斯联邦, Moscow
Gulnara Dibirova
N.I. Pirogov Russian National Research Medical University
Email: g.dibirova@mail.ru
ORCID iD: 0000-0002-1500-4974
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowNatalia Dmitrieva
N.I. Pirogov Russian National Research Medical University
Email: natapharm@gmail.com
Scopus 作者 ID: 7101760859
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowElena Kalinina
N.I. Pirogov Russian National Research Medical University
Email: lena_vk@mail.ru
Scopus 作者 ID: 8958305800
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowAnna Kirillova
N.I. Pirogov Russian National Research Medical University
Email: kirillova6@yandex.ru
ORCID iD: 0000-0003-3966-4448
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowNina Kiseleva
N.I. Pirogov Russian National Research Medical University
Email: kiseleva.67@mail.ru
ORCID iD: 0000-0003-1754-9051
MD, Cand. Sci. (Biol.), Professor
俄罗斯联邦, MoscowGerman Kukushkin
N.I. Pirogov Russian National Research Medical University
Email: germanpharm@yandex.ru
ORCID iD: 0000-0002-1661-1071
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowTatiana Leonteva
N.I. Pirogov Russian National Research Medical University
Email: leontevati@mail.ru
MD, Cand. Sci. (Biol.)
俄罗斯联邦, MoscowMaxim Maximov
N.I. Pirogov Russian National Research Medical University
Email: maksim_maksimov@mail.ru
ORCID iD: 0000-0002-8979-8084
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, MoscowElena Markina
N.I. Pirogov Russian National Research Medical University
Email: elvikmark2015@yandex.ru
ORCID iD: 0000-0002-5943-4423
俄罗斯联邦, Moscow
Svetlana Mileshina
N.I. Pirogov Russian National Research Medical University
Email: svetikshrv@rambler.ru
ORCID iD: 0000-0001-8082-9393
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowMaia Tsitsuashvili
N.I. Pirogov Russian National Research Medical University
Email: mayan318@gmail.com
ORCID iD: 0000-0001-7761-8683
MD, Cand. Sci. (Biol.)
俄罗斯联邦, MoscowDmitry Yurov
N.I. Pirogov Russian National Research Medical University
Email: dmpharm@gmail.com
ORCID iD: 0000-0003-0178-8736
MD, Cand. Sci. (Med.)
俄罗斯联邦, Moscow参考
- Onishchenko GG, Sizikova TE, Lebedev VN, Borisevich SV. Analysis of Promising Approaches to COVID-19 Vaccine Development. BIOpreparations. Prevention, Diagnosis, Treatment. 2020;20(4):216–227. (In Russ). doi: 10.30895/2221-996X-2020-20-4-216-227
- World Health Organisation [Internet] COVID-19 vaccines [cited 2021 Jun 8] Available from: www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
- Whocc.no [Internet]. Norwegian Institute of Public Health. Structure and principles [cited 2021 Jun 8] Available from: www.whocc.no/atc/structure_and_principles/
- Vigilyze.who-umc.org [Internet]. [cited 2021 Jun 8] Available from: https://vigilyze.who-umc.org
- Vigilyze.who-umc.org [Internet]. [cited 2021 Jun 8] Available from: https://vigilyze.who-umc.org/protected/report_1_covid-19_vaccines.html
- Vigilyze.who-umc.org [Internet]. [cited 2021 Jun 8] Available from: https://vigilyze.who-umc.org/protected/report_2_covid-19_vaccines.html
- Vigilyze.who-umc.org [Internet]. [cited 2021 Jun 8] Available from: https://vigilyze.who-umc.org/protected/report_3_covid-19_vaccines.html
- Vigilyze.who-umc.org [Internet]. [cited 2021 Jun 8] Available from: https://vigilyze.who-umc.org/protected/report_4_covid-19_vaccines.html
- Vigiaccess.org [Internet]. VigiAccessТМ. Upsala Monitoring Centre [cited 2021 Jun 8]. Available from: www.vigiaccess.org
补充文件
